Terms: = Prostate cancer AND FLI1, SIC-1, 2313, ENSG00000151702, Q01543, EWSR2
41 results:
1. Transcriptomes of prostate cancer with TMPRSS2:ERG and Other ETS Fusions.
Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
[TBL] [Abstract] [Full Text] [Related]
2. Prospective Clinical Genomic Profiling of Ewing Sarcoma:
Ogura K; Elkrief A; Bowman AS; Koche RP; de Stanchina E; Benayed R; Mauguen A; Mattar MS; Khodos I; Meyers PA; Healey JH; Tap WD; Hameed M; Zehir A; Shukla N; Sawyers C; Bose R; Slotkin E; Ladanyi M
JCO Precis Oncol; 2022 Aug; 6():e2200048. PubMed ID: 35952322
[TBL] [Abstract] [Full Text] [Related]
3. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.
Weiner AB; Yu CY; Kini M; Liu Y; Davicioni E; Mitrofanova A; Lotan TL; Schaeffer EM
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):105-112. PubMed ID: 35568781
[TBL] [Abstract] [Full Text] [Related]
4. Transcription factor Fli-1 as a new target for antitumor drug development.
Li L; Yu J; Cheng S; Peng Z; Luo H
Int J Biol Macromol; 2022 Jun; 209(Pt A):1155-1168. PubMed ID: 35447268
[TBL] [Abstract] [Full Text] [Related]
5. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract] [Full Text] [Related]
6. Allosteric interference in oncogenic fli1 and ERG transactions by mithramycins.
Hou C; Mandal A; Rohr J; Tsodikov OV
Structure; 2021 May; 29(5):404-412.e4. PubMed ID: 33275876
[TBL] [Abstract] [Full Text] [Related]
7. NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer.
Tang L; Zhang L; Liu L; Dong L; Dong Y; Zhu W; Wang H
FEBS Open Bio; 2020 Dec; 10(12):2678-2686. PubMed ID: 33058520
[TBL] [Abstract] [Full Text] [Related]
8. Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3', 5'-diprenylated Chalcone Inhibits Growth and Metastasis of prostate cancer Cells.
Ma Y; Xu B; Yu J; Huang L; Zeng X; Shen X; Ren C; Ben-David Y; Luo H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210104
[TBL] [Abstract] [Full Text] [Related]
9. Identifying FL11 subtype by characterizing tumor immune microenvironment in prostate adenocarcinoma via Chou's 5-steps rule.
Yang L; Lv Y; Wang S; Zhang Q; Pan Y; Su D; Lu Q; Zuo Y
Genomics; 2020 Mar; 112(2):1500-1515. PubMed ID: 31472243
[TBL] [Abstract] [Full Text] [Related]
10. Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA.
Kuan AS; Green J; Kitahara CM; Berrington De González A; Key T; K Reeves G; Floud S; Balkwill A; Bradbury K; Liao LM; Freedman ND; Beral V; Sweetland S;
Neuro Oncol; 2019 Jul; 21(7):944-952. PubMed ID: 30690490
[TBL] [Abstract] [Full Text] [Related]
11. Arterial thromboembolic events preceding the diagnosis of cancer in older persons.
Navi BB; Reiner AS; Kamel H; Iadecola C; Okin PM; Tagawa ST; Panageas KS; DeAngelis LM
Blood; 2019 Feb; 133(8):781-789. PubMed ID: 30578253
[TBL] [Abstract] [Full Text] [Related]
12. [Histopathology and molecular profile of a case of prostatic Ewing sarcoma].
Mora MF; de la Iglesia P; Isola M
Rev Esp Patol; 2018; 51(4):239-243. PubMed ID: 30269775
[TBL] [Abstract] [Full Text] [Related]
13. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing cancers.
Mitra P; Eckenrode JM; Mandal A; Jha AK; Salem SM; Leggas M; Rohr J
J Med Chem; 2018 Sep; 61(17):8001-8016. PubMed ID: 30114371
[TBL] [Abstract] [Full Text] [Related]
14. Bombesin Antagonist-Based Radiotherapy of prostate cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
Kim K; Zhang H; La Rosa S; Jebiwott S; Desai P; Kimm S; Scherz A; O'Donoghue JA; Weber WA; Coleman JA
Clin Cancer Res; 2017 Jul; 23(13):3343-3351. PubMed ID: 28108545
[No Abstract] [Full Text] [Related]
15. Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in prostate cancer Patients.
Castiello L; Sabatino M; Ren J; Terabe M; Khuu H; Wood LV; Berzofsky JA; Stroncek DF
Clin Cancer Res; 2017 Jul; 23(13):3352-3364. PubMed ID: 28073842
[No Abstract] [Full Text] [Related]
16. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
Chung V; Mansfield AS; Braiteh F; Richards D; Durivage H; Ungerleider RS; Johnson F; Kovach JS
Clin Cancer Res; 2017 Jul; 23(13):3277-3284. PubMed ID: 28039265
[No Abstract] [Full Text] [Related]
17. Locus-specific gene repositioning in prostate cancer.
Leshner M; Devine M; Roloff GW; True LD; Misteli T; Meaburn KJ
Mol Biol Cell; 2016 Jan; 27(2):236-46. PubMed ID: 26564800
[TBL] [Abstract] [Full Text] [Related]
18. The Molecular Taxonomy of Primary prostate cancer.
Cancer Genome Atlas Research Network
Cell; 2015 Nov; 163(4):1011-25. PubMed ID: 26544944
[TBL] [Abstract] [Full Text] [Related]
19. SLFN11 Is a Transcriptional Target of EWS-fli1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract] [Full Text] [Related]
20. Cyclin D1 is a useful marker for soft tissue Ewing's sarcoma/peripheral Primitive Neuroectodermal Tumor in children and adolescents: A comparative immunohistochemical study with rhabdomyosarcoma.
Magro G; Brancato F; Musumeci G; Alaggio R; Parenti R; Salvatorelli L
Acta Histochem; 2015; 117(4-5):460-7. PubMed ID: 25765111
[TBL] [Abstract] [Full Text] [Related]
[Next]
